New England Biolabs is focused on the discovery and development of recombinant and native enzymes for genomic research. It offers restriction endonucleases for DNA digestion; PCR, polymerases, and amplification technologies for PCR applications; DNA modifying enzymes and cloning technologies; reagents for DNA and RNA sample preparation; DNA, RNA, and protein markers and ladders for electrophoresis applications; reagents for RNA research; and gene expression tools for DNA, RNA, and protein transfection of cell lines. The company also offers cellular analysis solutions; reagents, enzymes, antibodies, and DNA controls for epigenetics research; protein expression and purification technologies; competent cells for transformation and protein expression; protein tools; glycobiology products; and plasmids and DNAs for use in cloning experiments. New England Biolabs was founded in 1974 and is based in Ipswich, Massachusetts.

Mycogen LLC manufactures and sells agricultural products. The company was founded by Andrew C. Barnes and David H. Rammler in 1982 and is headquartered in Indianapolis, IN.

Spine Wave engages in developing and marketing medical devices for the treatment of spinal disorders. It focuses on commercializing technology platforms that offer surgical solutions for spine surgeons and their patients. Spine Wave offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine as well as adjacent level systems. Spine Wave also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. John Pafford and Mark LoGuidice founded Spine Wave on February 1, 2001. It has its headquarters in Shelton in Connecticut.

EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).

Boston Biomedical Research Institute (BBRI) was a non-profit institution concentrating on basic biomedical research to promote the understanding of human diseases (including heart disease, cancer, muscular dystrophy and Alzheimer's etc.). It was located in Watertown, Massachusetts.

Provivi is developing biopesticides for agriculture, commercial, household, and public health pest management. It has a world-class team of founders, scientists, and advisors with significant experience in biotechnology (including biocatalysis), the fine chemicals industry, and, in particular, the agchem industry. It pursues disruptive opportunities enabled by breakthrough biological processes for making supply-limited products that are efficacious, safe, and environmentally benign. Provivi was founded in 2013 based on biocatalysis technology developed at the California Institute of Technology (Caltech) which has since become a licensor, shareholder, and research collaborator. It is based in Santa Monica, California.

Quintessence Biosciences, Inc., a biopharmaceutical company, develops novel protein-based therapeutics as anti-cancer agents. The company’s products include Evade RNase QBI-139 that causes tumor growth inhibition in breast, colorectal, non-small cell lung, ovarian, pancreatic, and prostate cancers; targeted EVade ribonucleases, a tumor targeting therapy; and EVade ribonuclease zymogens that are inactive enzyme precursors that proteolytically cleave to manifest their catalytic activity. Its products are based on the Evade ribonuclease technology that allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Upsher-Smith is dedicated to pursuit of innovative products that enable people to live life to its greatest potential.

Genecor, Inc. provides engineering services. The company is headquartered in Quebec City, Canada.

Dow Global Technologies LLC manufactures chemicals such as polymers.

Ed Geistlich S��hne AG F��r Chemische Industrie is a multi-national private company headquartered in Schlieren, Switzerland. The firm operates as holding company.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Infinitus (China) Co., Ltd., a subsidiary of Lee Kum Kee Group Ltd., is a company headquartered in Guangzhou, China, that develops, manufactures and distributes herbal health products.\nThe company says this about itself: Founded in 1992, Infinitus, a member of LKK Health Products Group, is a modern large-scale company that specializes in R&D, production, sales and services of Chinese herbal health products.

Atterx Biotherapeutics, Inc. develops novel antibacterial technologies. It developed two products to fight multi-drug resistant, Gram negative bacteria. The first product, C-1205 utilizes bacterial interference technology to prevent catheter associated urinary tract infections and GN-4474 has been developed using this technology to target Gram negative bacteria. It has been shown to be effective in animal infection models and an IND filing is expected in 2015. The company was founded by Richard R. Burgess and Marcin Filutowicz in 2001 and is headquartered in Madison, WI.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.